ADC Therapeutics SA
NYSE:ADCT
ADC Therapeutics SA
NYSE:ADCT
Price:
4.26 USD
-4.05%
Market Closed
Updated:
Apr 26, 2024
ADC Therapeutics SA
Income from Continuing Operations
|
ADC Therapeutics SA
Income from Continuing Operations Peer Comparison
Comparables:
ACIU
CRSP
BSLN
IDIA
KURN
Competitive Income from Continuing Operations Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | Income from Continuing Operations | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
|
ADC Therapeutics SA
NYSE:ADCT
|
Income from Continuing Operations
-$234.5m
|
CAGR 3-Years
2%
|
CAGR 5-Years
-14%
|
CAGR 10-Years
N/A
|
|
|
AC Immune SA
NASDAQ:ACIU
|
Income from Continuing Operations
-CHf54.2m
|
CAGR 3-Years
4%
|
CAGR 5-Years
-1%
|
CAGR 10-Years
N/A
|
|
|
CRISPR Therapeutics AG
NASDAQ:CRSP
|
Income from Continuing Operations
-$153.6m
|
CAGR 3-Years
24%
|
CAGR 5-Years
1%
|
CAGR 10-Years
N/A
|
|
|
Basilea Pharmaceutica AG
SIX:BSLN
|
Income from Continuing Operations
CHf10.5m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Idorsia Ltd
SIX:IDIA
|
Income from Continuing Operations
-CHf827.9m
|
CAGR 3-Years
-19%
|
CAGR 5-Years
-122%
|
CAGR 10-Years
N/A
|
|
|
Kuros Biosciences AG
SIX:KURN
|
Income from Continuing Operations
-CHf13.7m
|
CAGR 3-Years
-6%
|
CAGR 5-Years
-3%
|
CAGR 10-Years
N/A
|
See Also
What is ADC Therapeutics SA's Income from Continuing Operations?
Income from Continuing Operations
-234.5m
USD
-234.5m
USD
Based on the financial report for Dec 31, 2023, ADC Therapeutics SA's Income from Continuing Operations amounts to -234.5m USD.
What is ADC Therapeutics SA's Income from Continuing Operations growth rate?
Income from Continuing Operations CAGR 5Y
-14%
-14%
Over the last year, the Income from Continuing Operations growth was -51%. The average annual Income from Continuing Operations growth rates for ADC Therapeutics SA have been 2% over the past three years , -14% over the past five years .
You don't have any saved screeners yet
